Cargando…
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use of ICIs in combination with other forms of cancer t...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256840/ https://www.ncbi.nlm.nih.gov/pubmed/34215691 http://dx.doi.org/10.1136/jitc-2021-002896 |
_version_ | 1783718178240593920 |
---|---|
author | Reynolds, Kerry L Arora, Shaily Elayavilli, Ravikumar Komandur Louv, William C Schaller, Teilo H Khandelwal, Aakanksha Rothenberg, Mace Khozin, Sean Guidon, Amanda C Dougan, Michael Zubiri, Leyre Petrillo, Laura Sise, Meghan E Villani, Alexandra-Chloe Johnson, Douglas B Rahma, Osama Sharon, Elad |
author_facet | Reynolds, Kerry L Arora, Shaily Elayavilli, Ravikumar Komandur Louv, William C Schaller, Teilo H Khandelwal, Aakanksha Rothenberg, Mace Khozin, Sean Guidon, Amanda C Dougan, Michael Zubiri, Leyre Petrillo, Laura Sise, Meghan E Villani, Alexandra-Chloe Johnson, Douglas B Rahma, Osama Sharon, Elad |
author_sort | Reynolds, Kerry L |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use of ICIs in combination with other forms of cancer therapy, such as chemotherapy, radiotherapy, or targeted therapy, is also expanding. However, immune-related adverse events (irAEs) can be serious in up to a third of patients. Critical questions remain surrounding the characteristics and outcomes of irAEs, and how they may affect the overall risk–benefit relationship for combination therapies. This article proposes a framework for irAE classification and reporting, and identifies limitations in the capture and sharing of data on irAEs from current clinical trial and real-world data. We outline key gaps and suggestions for clinicians, clinical investigators, drug sponsors, patients, and other stakeholders to make these critical data more available to researchers for pooled analysis, to advance contemporary understanding of irAEs, and ultimately improve the efficacy of ICIs. |
format | Online Article Text |
id | pubmed-8256840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-82568402021-07-23 Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data Reynolds, Kerry L Arora, Shaily Elayavilli, Ravikumar Komandur Louv, William C Schaller, Teilo H Khandelwal, Aakanksha Rothenberg, Mace Khozin, Sean Guidon, Amanda C Dougan, Michael Zubiri, Leyre Petrillo, Laura Sise, Meghan E Villani, Alexandra-Chloe Johnson, Douglas B Rahma, Osama Sharon, Elad J Immunother Cancer Position Article and Guidelines Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use of ICIs in combination with other forms of cancer therapy, such as chemotherapy, radiotherapy, or targeted therapy, is also expanding. However, immune-related adverse events (irAEs) can be serious in up to a third of patients. Critical questions remain surrounding the characteristics and outcomes of irAEs, and how they may affect the overall risk–benefit relationship for combination therapies. This article proposes a framework for irAE classification and reporting, and identifies limitations in the capture and sharing of data on irAEs from current clinical trial and real-world data. We outline key gaps and suggestions for clinicians, clinical investigators, drug sponsors, patients, and other stakeholders to make these critical data more available to researchers for pooled analysis, to advance contemporary understanding of irAEs, and ultimately improve the efficacy of ICIs. BMJ Publishing Group 2021-07-02 /pmc/articles/PMC8256840/ /pubmed/34215691 http://dx.doi.org/10.1136/jitc-2021-002896 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Position Article and Guidelines Reynolds, Kerry L Arora, Shaily Elayavilli, Ravikumar Komandur Louv, William C Schaller, Teilo H Khandelwal, Aakanksha Rothenberg, Mace Khozin, Sean Guidon, Amanda C Dougan, Michael Zubiri, Leyre Petrillo, Laura Sise, Meghan E Villani, Alexandra-Chloe Johnson, Douglas B Rahma, Osama Sharon, Elad Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data |
title | Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data |
title_full | Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data |
title_fullStr | Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data |
title_full_unstemmed | Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data |
title_short | Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data |
title_sort | immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data |
topic | Position Article and Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256840/ https://www.ncbi.nlm.nih.gov/pubmed/34215691 http://dx.doi.org/10.1136/jitc-2021-002896 |
work_keys_str_mv | AT reynoldskerryl immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT arorashaily immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT elayavilliravikumarkomandur immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT louvwilliamc immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT schallerteiloh immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT khandelwalaakanksha immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT rothenbergmace immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT khozinsean immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT guidonamandac immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT douganmichael immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT zubirileyre immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT petrillolaura immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT sisemeghane immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT villanialexandrachloe immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT johnsondouglasb immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT rahmaosama immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata AT sharonelad immunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsacalltoactionforcollectingandsharingclinicaltrialandrealworlddata |